In our studies, we observed an increase in CD4+ T cells in idMMR neuroblastoma tumors (Figure 2G); therefore, we decided to treat the tumor-bearing animals with an anti-CTLA4, which mainly depends on CD4+ T cells for its effectiveness.39 This evidence concerns the gene CD4 and neuroblastoma.